London: Long Covid is less likely among the vaccinated before infections, but among those unvaccinated, the risk is four times more, a study revealed.
The study published by The BMJ showed that receiving at least one dose of Covid-19 vaccine before the first infection is strongly associated with a reduced risk of developing long Covid.
Researchers from the University of Gothenburg, Sweden, said their results “highlight the importance of primary vaccination against Covid-19 to reduce the burden of post-Covid conditions in the population”.
The team investigated the effectiveness of primary Covid vaccination (the first two doses and the first booster dose within the recommended schedule) against Long Covid conditions in 589,722 adults (aged 18 and over).
Individuals were followed from a first Covid infection until a diagnosis of Long Covid condition, vaccination, reinfection, death, emigration or end of follow-up whichever came first. The average follow-up was 129 days in the total study population (vaccinated: 197 days, not vaccinated: 112 days).
Of the 299,692 vaccinated individuals with Covid, 1,201 were diagnosed with Long Covid during follow-up, compared with 4,118 of 290,030 unvaccinated individuals.
Those who received one or more Covid vaccine before the first infection were 58 per cent less likely to receive a diagnosis of post-Covid condition than unvaccinated individuals.
And vaccine effectiveness increased with each successive dose before infection (a dose-response effect).
This is an observational study, which provides less conclusive evidence of causality, and the researchers point to several limitations such as limited data on post-Covid condition symptoms and that the diagnosis code is not yet validated, the potential impact of reinfections on vaccine effectiveness, and expectations about the protective effect of vaccination.
The findings, combined with evidence from other studies, highlight the association between the immune system and the development of post-viral conditions, and underline the importance of timely vaccination during pandemics, said researchers in a linked editorial.
They called for continued investigation into the evolution of long-term residual symptoms of Covid and other viral illnesses as well as steps to “improve the accuracy of recording both recovery and continued illness after infection, and in quantifying key family, social, financial, and economic outcomes”.
“Such estimates are fundamental to unlocking the funding required for future research and increased investment in specialist clinical services offering treatment and rehabilitation to support patients with post-viral conditions,” they said.
